The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Non-Muscle Invasive Bladder Cancer Market In 2026 And What Value Is Projected For 2030?
The non-muscle invasive bladder cancer market has shown robust growth in recent years. It is forecast to increase from $3.66 billion in 2025 to $3.87 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The expansion observed historically can be linked to factors such as the early diagnosis of bladder cancer, a reliance on transurethral resection, the limited adoption of intravesical therapy, the development of hospital pharmacy infrastructure, and a low awareness of nmibc staging.
The non-muscle invasive bladder cancer market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $4.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. Factors driving this growth during the forecast period include the increasing prevalence of bladder cancer, the greater uptake of immunotherapy and chemotherapy, the expansion of online and retail pharmacy channels, the broader utilization of advanced diagnostic imaging, and the progress in personalized treatment methods. Key developments expected over the forecast period encompass the growing adoption of AI-powered diagnostic tools, the increased application of genomics and precision medicine strategies, the broader implementation of data-driven clinical decision support, the wider deployment of minimally invasive therapeutic techniques, and the progressing integration of connected health monitoring solutions.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20904&type=smp
What Major Drivers Are Influencing Demand In The Non-Muscle Invasive Bladder Cancer Market?
An increasing emphasis on personalized medicine is anticipated to drive expansion in the non-muscle invasive bladder cancer market in the future. This approach entails tailoring medical care to an individual’s unique genetic makeup, way of life, and surroundings to achieve better outcomes. The heightened focus on personalized medicine stems from multiple factors, including breakthroughs in genomic research, enhanced diagnostic instruments, and a rising need for more precise and impactful therapies. Non-muscle invasive bladder cancer facilitates personalized medicine by allowing for customized treatment regimens that consider specific tumor attributes, genetic indicators, and unique patient details. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, these developments are stimulating growth within the non-muscle invasive bladder cancer market.
What Are The Key Segments Of The Non-Muscle Invasive Bladder Cancer Market?
The non-muscle invasive bladder cancer market covered in this report is segmented –
1) By Stage: Carcinoma In Situ (CIS), T1 Stage, Ta Stage
2) By Treatment: Immunotherapy, Chemotherapy, Surgery, Intravesical Therapy, Other Treatments
3) By Tumor: Low-Grade Tumours, High-Grade Tumours
4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Carcinoma In Situ (CIS): High-Grade CIS, Low-Grade CIS
2) By T1 Stage: T1a Stage (Superficial Tumors), T1b Stage (Invasive Into Lamina Propria)
3) By Ta Stage: Low-Grade Ta Stage, High-Grade Ta Stage
What Key Trends Are Influencing The Development Of The Non-Muscle Invasive Bladder Cancer Market?
Leading companies within the non-muscle invasive bladder cancer market are prioritizing the development of innovative products, such as immunotherapy, to enhance treatment possibilities and patient outcomes. Immunotherapy functions by leveraging the body’s immune system to identify and combat cancer cells through the augmentation or activation of immune responses. For example, in March 2024, ImmunityBio Inc., a biotechnology company located in the US, obtained approval from the Food and Drug Administration (FDA) for ANKTIVA (N-803) to treat patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) presenting with carcinoma in situ (CIS), either with or without papillary tumors. This approval is supported by encouraging clinical trial data, demonstrating that ANKTIVA, when administered with Bacillus Calmette-Guérin (BCG), provides a feasible treatment alternative for patients who have not responded to standard BCG therapy. ANKTIVA is a groundbreaking IL-15 agonist immunotherapy that operates by strengthening the immune system, specifically by stimulating natural killer (NK) cells and CD8+ killer T cells to target and eradicate cancer cells.
Who Are The Leading Companies Operating In The Non-Muscle Invasive Bladder Cancer Market?
Major companies operating in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co Inc, AstraZeneca plc, Astellas Pharma US Inc, EMD Serono Inc, Genentech Inc, Aura Biosciences Inc, UroGen Pharma Ltd, Protara Therapeutics Inc, Istari Oncology Inc, Heat Biologics Inc, Viventia Bio Inc, ImmunityBio Inc, Altor BioScience Corporation, SURGE Therapeutics Inc, Pfizer Inc, Hoffmann‑La Roche Ltd, CG Oncology Inc, Tyra Biosciences Inc, Prokarium Ltd, ImmVira Pharma Co Ltd, Trigone Pharma Ltd, enGene Holdings Inc, Atonco Pharma Ltd.
Read the full non-muscle invasive bladder cancer market report here:
Which Region Shows The Strongest Potential For Future Growth In The Non-Muscle Invasive Bladder Cancer Market?
North America was the largest region in the non-muscle invasive bladder cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-muscle invasive bladder cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-Muscle Invasive Bladder Cancer Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20904&type=smp
Browse Through More Reports Similar to the Global Non-Muscle Invasive Bladder Cancer Market 2026, By The Business Research Company
Prenatal Testing And Newborn Screening Global Market Report
Prenatal And Newborn Genetic Testing Global Market Report
Pregnancy Test Kits Global Market Report
https://www.thebusinessresearchcompany.com/report/pregnancy-test-kits-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model